Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up
Stock Investor Wire

FATE Quote, Trading Chart, Fate Therapeutics Inc.


home / stock / fate / fate quote

$89.72 Last:

4.0% Change Percent:

$88.67 Open:

$89.72 Previous Close:

$93.285 High:

$84.02 Low:

1,195,120 Volume:

02/26/2021 04:55:33 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Last Five Trading Days

Stock DateOpen PriceClose PriceHighLowVolume
2021-02-2688.6789.7293.28584.021,195,120
2021-02-2597.686.27100.7485.721,243,453
2021-02-2496.8295.2798.968892.501695,010
2021-02-2396.6895.4898.3387.121,698,835
2021-02-22107.73100.96108.03100.011,183,549
2021-02-19103.61110.18118.14103.51,542,635
2021-02-18100.51102.1103.898.4828,123
2021-02-17102.02103.22104.0996.43982,961
2021-02-16104.5101.44107.43100.71624,923
2021-02-15100.66102.45103.6498.88587,875
2021-02-12100.66102.45103.6498.88586,826
2021-02-11105.14102.5107.76101.83805,896
2021-02-10106.17103.31109.59100.37626,521
2021-02-09108.2105.32109.2875104.39510,760
2021-02-08105.74108.5109.96104.96693,909
2021-02-05104.97105.19107.3102.19558,571
2021-02-04100.69102.62104.9999.51623,546
2021-02-0399.298.24102.6297.0291827,112
2021-02-029697.49100.3295916,582
2021-02-0191.7193.1694.4590.25914,858
Stock Information

Fate Therapeutics Inc. Company Name:

FATE Stock Symbol:

NASDAQ Market:

Fate Therapeutics Inc. Website:

MENU
FATE FATE Quote FATE Short FATE News FATE Articles FATE Message Board
Get FATE Alerts

News, Short Squeeze, Breakout and More Instantly...

Stock Investor Wire
RECENT FATE NEWS
  • FATE - Fate Therapeutics Inc (FATE) Q4 2020 Earnings Call Transcript

    Image source: The Motley Fool. Fate Therapeutics Inc (NASDAQ: FATE) Q4 2020 Earnings Call Feb 24, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Fate Therapeutics Inc (FATE) Q4 2020 Earnings Call Transcript

  • FATE - Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress

    Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3 Clinical Activity of FT596 as Monotherapy Demonstrated in Refractory DLBCL; Partial Re...

  • FATE - Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

    SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced t...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your Twitter Account

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.


Sign up or login to continue

Sign up or login to continue.


Forgot password?




WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Member Benefits

Member Coins


Log In

Sign Up

Stay Connected
Follow @marketWN

Contact

Privacy

Terms of Service

Disclaimer

© 2020 Market Wire News